Table 1.
Clinical and demographic characteristics of study participants by vital status
| Variables of interest | Vital status |
P value | |
|---|---|---|---|
| Alive N = 3010 (77.9%) |
Deceased N = 856 (22.1%) |
||
| Age at completing the survey in y | |||
| Median (range) | 56 (18-83) | 60 (18-84) | <.0001 |
| Age at completing the survey, n (%) | |||
| ≤56y | 1492 (49.6) | 328 (38.3) | <.0001 |
| >56y | 1518 (50.4) | 528 (61.7) | |
| Follow-up from completing the survey to death or end offollow-upin y | |||
| Median (range) | 6 (1-22) | 4 (0-22) | <.0001 |
| BMT era, n (%) | |||
| 1974-1989 | 210 (7.0) | 108 (12.6) | <.0001 |
| 1990-2004 | 1249 (41.5) | 418 (48.8) | |
| 2005-2014 | 1551 (51.5) | 330 (38.5) | |
| Sex, n (%) | |||
| Female | 1428 (47.4) | 308 (36.0) | <.0001 |
| Male | 1582 (52.6) | 548 (64.0) | |
| Race/ethnicity, n (%) | |||
| African American | 154 (5.1) | 30 (3.5) | .1131 |
| Non-Hispanic White | 2204 (73.2) | 654 (76.4) | |
| Hispanic | 398 (13.2) | 112 (13.1) | |
| Asian | 168 (5.6) | 34 (4.0) | |
| Other∗ | 83 (2.8) | 26 (3.0) | |
| Missing | 3 (0.1) | 0 (0.0) | |
| Health insurance, n (%) | |||
| Not insured | 98 (3.3) | 34 (4.0) | .2700 |
| Insured | 2887 (95.9) | 801 (93.6) | |
| Missing | 25 (0.8) | 21 (2.4) | |
| Annual household income, n (%) | |||
| <$19 999 | 848 (28.2) | 250 (29.2) | <.0001 |
| $20 000-$49 999 | 510 (16.9) | 219 (25.6) | |
| >$50 000 | 1366 (45.4) | 313 (36.6) | |
| Missing | 286 (9.5) | 74 (8.6) | |
| Educational status, n (%) | |||
| High school or less | 535 (17.8) | 179 (20.9) | .0411 |
| Post high school education | 2436 (80.9) | 669 (78.2) | |
| Missing | 39 (1.3) | 8 (0.9) | |
| Age at BMT in y | |||
| Median (IQR) | 43 (0-74) | 50 (1-72) | <.0001 |
| Follow-up from BMT to completing the survey in y | |||
| Median (range) | 9 (2-41) | 7 (2-37) | <.0001 |
| BMI, n (%) | |||
| Underweight (<18.5 kg/m2) | 97 (3.2) | 32 (3.7) | .3824 |
| Normal weight (18.5-<25 kg/m2) | 979 (32.5) | 260 (30.4) | |
| Overweight (25-<30 kg/m2) | 897 (29.8) | 243 (28.4) | |
| Obese (≥30 kg/m2) | 592 (19.7) | 138 (16.1) | |
| Unknown | 445 (14.8) | 183 (21.4) | |
| Primary diagnosis, n (%) | |||
| AML/MDS/ALL | 986 (32.8) | 237 (27.7) | <.0001 |
| CML | 282 (9.4) | 112 (13.1) | |
| HL/NHL | 978 (32.5) | 273 (31.9) | |
| PCD | 475 (15.8) | 213 (24.9) | |
| Other† | 289 (9.6) | 21 (2.4) | |
| Disease status at first BMT, n (%) | |||
| High risk | 1246 (41.4) | 483 (56.4) | <.0001 |
| Standard risk | 1371 (45.5) | 331 (38.7) | |
| Missing | 393 (13.1) | 42 (4.9) | |
| BMT type/cGvHD, n (%) | |||
| Autologous | 1443 (47.9) | 501 (58.5) | <.0001 |
| Allogeneic with cGvHD | 794 (26.4) | 246 (28.7) | |
| Allogeneic without cGvHD | 718 (23.8) | 104 (12.2) | |
| Allogeneic missing cGvHD | 55 (1.8) | 5 (0.6) | |
| Stem cell source, n (%) | |||
| Bone marrow/cord blood | 1034 (34.3) | 265 (31.0) | .0627 |
| Peripheral stem cells | 1975 (65.6) | 591 (69.0) | |
| Missing | 1 (0.03) | 0 (0.0) | |
| Conditioning intensity, n (%) | |||
| MAC | 2062 (68.5) | 611 (71.4) | <.0001 |
| RIC/NMA | 647 (21.5) | 114 (13.3) | |
| Missing | 301 (10.0) | 313 (15.3) | |
| Conditioning agents, n (%) | |||
| TBI | 1324 (44.0) | 424 (49.5) | .0040 |
| Cyclophosphamide | 1601 (53.2) | 416 (48.6) | .0177 |
| Nitrosoureas | 414 (13.8) | 87 (10.2) | .0058 |
| Etoposide | 1056 (35.1) | 279 (32.6) | .1765 |
| Busulfan | 363 (12.1) | 48 (5.6) | <.0001 |
| Cytarabine | 199 (6.6) | 54 (6.3) | .7519 |
| Melphalan | 782 (26.0) | 226 (26.4) | .8041 |
| Fludarabine | 519 (17.2) | 80 (9.4) | <.0001 |
| Chronic health conditions, n (%) | |||
| Grade 3 or 4 | 1694 (56.3) | 560 (65.4) | <.0001 |
| Mental health‡, n (%) | |||
| Not impaired | 2892 (96.1) | 779 (91.0) | <.0001 |
| Impaired | 118 (3.9) | 77 (9.0) | |
| Some pain from cancer, n (%) | |||
| No | 921 (30.6) | 264 (30.8) | .7931 |
| Yes | 2065 (68.6) | 579 (67.6) | |
| Missing | 24 (0.8) | 13 (1.5) | |
| Anxiety from cancer treatments, n (%) | |||
| Absent | 2821 (93.7) | 784 (91.6) | .7439 |
| Present | 139 (4.6) | 41 (4.8) | |
| Missing | 50 (1.7) | 31 (3.6) | |
| Ever smoke, n (%) | |||
| No | 1992 (66.2) | 438 (51.2) | <.0001 |
| Yes | 1005 (33.4) | 410 (47.9) | |
| Missing | 13 (0.4) | 8 (0.9) | |
| Smoking status, n (%) | |||
| Never smoker | 1992 (66.2) | 438 (51.2) | <.0001 |
| Former smoker | 863 (28.7) | 352 (41.1) | |
| Current smoker | 142 (4.7) | 58 (6.8) | |
| Missing | 13 (0.4) | 8 (0.9) | |
| Ever drink alcohol, n (%) | |||
| No | 1395 (46.3) | 268 (31.3) | <.0001 |
| Yes | 1577 (52.4) | 562 (65.7) | |
| Missing | 38 (1.3) | 26 (3.0) | |
| Heavy drinker, n (%) | |||
| No | 1464 (90.7) | 485 (82.5) | <.0001 |
| Yes | 113 (7.0) | 77 (13.1) | |
| Missing | 38 (2.3) | 26 (4.4) | |
| Vigorous physically active, n (%) | |||
| No | 1572 (52.2) | 403 (47.1) | .029 |
| Yes | 1421 (47.2) | 448 (52.3) | |
| Missing | 17 (0.6) | 5 (0.6) | |
| Levels of vigorous exercise (total metabolic equivalent h/wk-1) | |||
| 0 MET h/wk-1 | 1748 (58.1) | 578 (67.5) | <.0001 |
| 3 to <9 MET h/wk-1 | 964 (32.0) | 120 (14.0) | |
| ≥9 MET h/wk-1 | 281 (9.3) | 153 (17.9) | |
| Missing | 17 (0.6) | 5 (0.6) | |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BMI, body mass index; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; IQR, interquartile range; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; NMA, nonmyeloablative; NHL, non-Hodgkin lymphoma; PCD, plasma cell dyscrasias; RIC, reduced intensity conditioning.
Bold indicates statistically significant (P < 0.05).
∗
Race other includes multiracial (n = 94), American Indian (n = 13), and Pacific Islander (n = 2).
†
Primary diagnosis other includes severe aplastic anemia, other leukemia, and other.
‡
Mental health is impaired if T-score ≥63 on any 2 of symptom scales of the 3 Brief Symptom Inventory-18 items subscales (depression, somatization, or anxiety).